Streetbeat News

Earnings

CARR

HON

Honeywell has completed the acquisition of Carrier Global's Global Access Solutions business for $4.95 billion. Following the acquisition, Honeywell has updated its 2024 outlook, including full-year sales, segment margin, and adjusted earnings per share guidance under amended non-GAAP reporting metrics.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 11:00 am

SAIC

Science Applications International Corporation (SAIC) reported its Q1 2025 adjusted EPS of $1.92, which was in line with expectations. The company also reported sales of $1.847 billion, slightly beating the estimate of $1.844 billion.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 10:59 am

BDX

EW

BD (Becton, Dickinson and Company) expects its acquisition of Edwards Lifesciences' Critical Care business to be immediately accretive to all key financial measures. The deal, valued at approximately $4.2 billion, will be funded with $1 billion in cash and $3.2 billion in new debt.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 10:36 am

CLDT

Chatham Lodging Trust (NYSE:CLDT) reported a strong 5% RevPAR growth through May, exceeding its second quarter guidance of 2.5% to 4.0%. Key markets like Silicon Valley and Bellevue saw significant growth, with other strong markets including Cherry Creek, Dallas, Greater New York, San Antonio, and San Diego.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 10:35 am

AGIO

Agios Pharmaceuticals announced that its Phase 3 ENERGIZE-T study of mitapivat in adults with transfusion-dependent thalassemia met its primary and key secondary endpoints, showing significant reduction in transfusion burden compared to placebo.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 10:32 am

BDX

EW

Edwards Lifesciences has entered a definitive agreement to sell its Critical Care Product Group to BD for $4.2 billion in an all-cash transaction. The deal is expected to close by the end of 2024, subject to regulatory approvals. Edwards will use the proceeds for strategic growth investments.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 10:31 am

NVDA

Nvidia's stock surged 3% in premarket trading following a compelling presentation by CEO Jensen Huang at Computex 2024. The presentation highlighted the next-gen AI accelerator Rubin, AI factories, and Nvidia Inference Micro Services. Analyst Pierre Ferragu praised the keynote, contributing to Nvidia's stock performance.

Portfolio Pulse from Shanthi Rexaline

June 03, 2024 | 10:10 am

PFE

TAK

Takeda and Pfizer announced positive Phase 3 HD21 trial results for Adcetris (Brentuximab Vedotin) in combination with chemotherapy, showing superior progression-free survival and improved tolerability compared to the current standard of care in Europe.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 9:01 am

JAZZ

Jazz Pharmaceuticals presented updated survival data from the HERIZON-BTC-01 trial of Zanidatamab in HER2-Positive Biliary Tract Cancer at ASCO 2024. The trial showed a median overall survival of 15.5 months for patients with IHC 2+ or 3+ and 18.1 months for patients with IHC 3+ tumors. The median duration of response increased to 14.9 months with approximately two years of follow-up.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 8:57 am

NUVB

Nuvation Bio announced positive results from the Phase 2 TRUST-I trial of their experimental ROS1 inhibitor, Taletrectinib, at ASCO 2024. Tumors shrank in 91% of TKI-naïve patients and 52% of TKI-pretreated patients with advanced ROS1-positive NSCLC. Responses were durable, with 71% of TKI-naïve patients still progression-free at two years.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 8:49 am